Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05019014 · ClinicalTrials.gov registry record
Olfactory Deficits in Neurologic Disease
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 201
- Enrollment target
NCT05019014: Completed study, sponsored by Massachusetts General Hospital.
NCT05019014 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 201 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05019014 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 201 participants
- Enrollment target
Study Summary
The goal of this study is to examine olfactory function in preclinical subjects or individuals with neurological diseases such as Probable Alzheimer's Disease (PRAD), Frontotemporal Dementias (FTD), Dementia with Lewy Bodies (DLB), Traumatic Brain Injury (TBI), and Amyotrophic Lateral Sclerosis (ALS).
Primary Outcome
Poor POEM status determined by comparing the predicted POEM score with the actual POEM score will correlate with entorhinal cortical thickness, and neuropsychological test results.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2011-08-10 |
| Est. Completion | 2020-07-03 |
What the finished NCT05019014 record still lists
NCT05019014 is an observational study that tracks outcomes without assigning an intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05019014 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05019014 about?
NCT05019014 is a clinical study titled "Olfactory Deficits in Neurologic Disease". The goal of this study is to examine olfactory function in preclinical subjects or individuals with neurological diseases such as Probable Alzheimer's Disease (PRAD), Frontotemporal Dementias (FTD), Dementia with Lewy Bodies (DLB), Traumatic Brain Injury (TBI), and Amyotrophic Lateral Sclerosis (ALS...
What is the current status of trial NCT05019014?
This trial is currently completed. The enrollment target is 201 participants. The study started on 2011-08-10. Estimated completion is 2020-07-03.
Who is sponsoring clinical trial NCT05019014?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI